1 / 28

4 th Annual Healthcare Informatics Symposium April 29 th , 2011 Richard ‘RJ’ Kedziora

Design and Implementation of a Diabetes Medication Computer Assisted Decision Support (CADS) System. 4 th Annual Healthcare Informatics Symposium April 29 th , 2011 Richard ‘RJ’ Kedziora. Funding / Disclosures. Founding Partner/Owner - Estenda Solutions Funding from

kiefer
Download Presentation

4 th Annual Healthcare Informatics Symposium April 29 th , 2011 Richard ‘RJ’ Kedziora

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Design and Implementation of a Diabetes Medication Computer Assisted Decision Support (CADS) System 4th Annual Healthcare Informatics Symposium April 29th, 2011 Richard ‘RJ’ Kedziora

  2. Funding / Disclosures • Founding Partner/Owner - Estenda Solutions • Funding from • U.S. Army Medical Research and Materiel Command (USARMC) AMEDD Advanced Medical Technology Initiative (AAMTI) program. • Congressionally Directed Medical Research Programs administered by Air Force in partnership with University of Pittsburgh Medical Center - sponsored by the honorable U.S. Representative John P. Murtha • PI on grant COL. Robert Vigersky M.D. at Walter Reed Army Medical Center

  3. The Problem • Not enough endocrinologist to treat patients with diabetes – most care is managed by primary care doctors • Most patient’s not goal (A1C 6.5 – 7%) • SMBG Issues • SMBG not used effectively by patients / providers • SMBG perception is that it is not used to adjust medications • Large number of drug and combinations • Therapy is not adjusted frequently enough

  4. Potential Medication Combinations • Drug classes include: biguanide, DPP-4 inhibitor, GLP-1 agonist, secretagogue, TZD, AGI, and basal insulin • Excluded: Colesevelam and Bromocriptine • 68 potential treatment combinations • 8 mono • 26 dual • 31 triple • 3 quadruple

  5. The Solution - CADS • Designed for primary care doctors to assist in better decision-making in modifying patient’s drug regimen to bring their blood glucose into better control. • Currently Type 2 (Type 1 planning) • Idea, concept and rules developed by • COL. Robert Vigersky, M.D. - Director, Diabetes Institute, Endocrinology Service, Department of Medicine, Walter Reed Army Health Care System, Washington DC • David Rodbard, M.D. – Biomedical Informatics Consultants, LLC, Potomac, Maryland

  6. Journey • Multiple facilitated group clinical chart reviews to reach consensus • Initial standalone prototype development using CLIPS and Microsoft ASP – early 2000s • Experimented with DROOLS moved to table-driven algorithm coded in Java • Production system coding and integration with CDMP 2009-2010 • Clinical Trial 2011 – 2012 and beyond • FDA Validation

  7. Input • Age, Gender, Type of Diabetes • Self-managed blood glucose data (SMBG) • Current and past medications • Adverse Reactions • Labs (A1C, ALT, Creatinine) • Significant Diagnoses • Renal, Hepatic, Gastrointestinal, Cardiac • Target A1C

  8. SMBG Testing Protocol • For 3 months • Twice daily (or more depending on DR. discretion) • Once a week • Before meals (x3) and bedtime = 4 tests • Once a month • Before and 2 hours after meals (x3), bedtime and night at approximately 3AM = 8 tests

  9. Pre-Analysis • Availability of SMBG • SMBG correlation with most recent A1c • Identification of problem time-frames based on SMBG data • Hypoglycemia • Hyperglycemia • Variability

  10. Analysis • Overall quality of glycemic control • Effectiveness of SMBG testing • Inappropriate medication combinations • Existing Medication Contraindications • Age, Gender, Labs, Diagnoses • Based on SMBG profile analysis and medication effectiveness • First, address Hypoglycemia • Then address Hyperglycemia

  11. Algorithm for Treatment of Type 2 Diabetes Diet and Exercise If A1C > 6.5% Monotherapy or Combination Therapy Not adequate Adequate Follow-up q 3 mo Other Oral Combinations Not adequate Adequate Follow-up q 3 mo Oral Agent Plus Insulin at Bedtime (Glargine or NPH) Not adequate Adequate Split-Mixed Insulin or Lispro or Aspartqac + Glargine or NPH qhs Follow-up q 3 mo

  12. Recommendations • Modify the existing regimen because of contraindications • Increase or decrease the dosage of current medication(s) • Add additional oral agents/basal insulin • 5+ medications or 4 with hyperglycemia - recommendation to consult endocrinologist

  13. Additional Output • Where testing can be improved • FDA Warnings • Rosiglitazone use has been severely restricted by the FDA because of concerns that it causes an increased number of cardiovascular events. Continued use requires your patient be enrolled in a risk evaluation and mitigation strategy program established by GlaxoSmithKline. You should consider switching this patient to pioglitazone at an equivalent dose… • SMBG Profile by Time Period • Min, Max, Average, Standard Deviation • % high, % low based on thresholds

  14. Algorithm Development • Started with Expert Rules System • Initially used CLIPS • Migrated to DROOLS • Final solution - Table-driven logic with algorithm coded in Java • Number of combinations • Ability for versioning and customization by individual non-rule experts

  15. Next Steps • A one-year multi-site IRB-approved, cluster-randomized controlled trial • Expand rule base to include • Insulin dependant Type 2 • Type 1 • Expanded pattern recognition and treatment plans • Post-prandial fluctuations • Trends during day or night • Hypoglycemia followed by rebound "Somogyi reaction“ • Dawn Phenomenon

  16. Publication • Rodbard and Vigersky, Design of a Decision Support System to Help Clinicians Manage Glycemia in Patients with Type 2 Diabetes • Journal of Diabetes Science and Technology, • Volume 5, Issue 2, March 2011

  17. Thank you! Richard ‘RJ’ Kedziora rkedziora@estenda.com Office: (610) 834-2908 Cell: (610) 772-3989

  18. CDMP Background • Complete customizable web-based clinical application for management of patients with chronic disease. • Based on the Chronic Care Model, it was originally designed for military healthcare to better manage patients with diabetes. • Evolved into a generalized chronic disease and population health management system supporting the Patient Centered Medical Home model.  For details visit: http://cdmp.estenda.com

More Related